Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5687)
All Articles published online
|
Publishing Process of This Article
|
Sep 7, 2013 (publication date) through Nov 5, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Jin JL, Hu P, Lu JH, Luo SS, Huang XY, Weng XH, Zhang JM. Lactic acidosis during telbivudine treatment for HBV: A case report and literature review. World J Gastroenterol 2013; 19(33): 5575-5580 [PMID: 24023503 DOI: 10.3748/wjg.v19.i33.5575] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v19/i33/5575.htm |
| Number | Citing Articles |
| 1 |
|
| 2 |
Yan Hong Wang, Ben Quan Wu, Hui Liu. Continuous venovenous hemodiafiltration for hyperlactatemia caused by telbivudine in a patient with chronic hepatitis B: A case report and update review. Journal of Digestive Diseases 2015; 16(3): 164 doi: 10.1111/1751-2980.12173
|
| 3 |
Li Chen, Cai Cheng, Bicui Chen, Yue Zhao, Jiming Zhang, Bin Wang. Cumulative incidence and risk factors of creatine kinase elevation associated with telbivudine. European Journal of Clinical Pharmacology 2016; 72(2): 235 doi: 10.1007/s00228-015-1978-9
|
| 4 |
Lung-Yi Mak, Wai-Kay Seto, Ching-Lung Lai, Man-Fung Yuen. DNA polymerase inhibitors for treating hepatitis B: a safety evaluation. Expert Opinion on Drug Safety 2016; 15(3): 383 doi: 10.1517/14740338.2016.1139573
|
| 5 |
Tomica Ambang, Joo-San Tan, Sheila Ong, Kum-Thong Wong, Khean-Jin Goh, Jose Ignacio Herrero. Clinicopathological Features of Telbivudine-Associated Myopathy. PLOS ONE 2016; 11(9): e0162760 doi: 10.1371/journal.pone.0162760
|
| 6 |
S. K. Sarin, M. Kumar, G. K. Lau, Z. Abbas, H. L. Y. Chan, C. J. Chen, D. S. Chen, H. L. Chen, P. J. Chen, R. N. Chien, A. K. Dokmeci, Ed Gane, J. L. Hou, W. Jafri, J. Jia, J. H. Kim, C. L. Lai, H. C. Lee, S. G. Lim, C. J. Liu, S. Locarnini, M. Al Mahtab, R. Mohamed, M. Omata, J. Park, T. Piratvisuth, B. C. Sharma, J. Sollano, F. S. Wang, L. Wei, M. F. Yuen, S. S. Zheng, J. H. Kao. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatology International 2016; 10(1): 1 doi: 10.1007/s12072-015-9675-4
|
| 7 |
Bircan Kayaaslan, Rahmet Guner. Adverse effects of oral antiviral therapy in chronic hepatitis B. World Journal of Hepatology 2017; 9(5): 227-241 doi: 10.4254/wjh.v9.i5.227
|
| 8 |
Ingrid Jullian-Desayes, Jean-Christian Borel, Fabrice Guerber, Anne-Laure Borel, Renaud Tamisier, Patrick Levy, Carole Schwebel, Jean-Louis Pepin, Marie Joyeux-Faure. Drugs influencing acid base balance and bicarbonate concentration readings. Expert Review of Endocrinology & Metabolism 2016; 11(2): 209 doi: 10.1586/17446651.2016.1147951
|
| 9 |
Long Jianfei, Wang Min, Ma Chunlai, Chen Bicui, Zhang Jiming, Wang Bin. The Ca 2+ /CaMKK2 axis mediates the telbivudine induced upregulation of creatine kinase: Implications for mechanism of antiviral nucleoside analogs’ side effect. Biochemical Pharmacology 2017; 146: 224 doi: 10.1016/j.bcp.2017.10.005
|
| 10 |
G. L.‐H. Wong, W.‐K. Seto, V. W.‐S. Wong, M.‐F. Yuen, H. L.‐Y. Chan. Review article: long‐term safety of oral anti‐viral treatment for chronic hepatitis B. Alimentary Pharmacology & Therapeutics 2018; 47(6): 730 doi: 10.1111/apt.14497
|
| 11 |
Zachary R. Smith, Michelle Horng, Megan A. Rech. Medication‐Induced Hyperlactatemia and Lactic Acidosis: A Systematic Review of the Literature. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2019; 39(9): 946 doi: 10.1002/phar.2316
|
| 12 |
Christos Triantos, Maria Kalafateli, Ioanna Aggeletopoulou, Martha Mandellou, Stelios Assimakopoulos, Paraskevi Tselekouni, Dimitra Taprantzi, Giorgos Tsiaoussis, Georgia Vourli, Evangelos D. Anastassiou, Charalambos Gogos, Chrisoula Labropoulou-Karatza, Konstantinos Thomopoulos. Lactate serum concentrations during treatment with nucleos(t)ide analogues in hepatitis B with or without cirrhosis. European Journal of Gastroenterology & Hepatology 2017; 29(9): 998 doi: 10.1097/MEG.0000000000000924
|
| 13 |
James Fung, Wai‐Kay Seto, Ching‐Lung Lai, Man‐Fung Yuen. Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. Journal of Gastroenterology and Hepatology 2014; 29(3): 428 doi: 10.1111/jgh.12499
|
| 14 |
Jianfei Long, Min Wang, Bicui Chen, Jiming Zhang, Bin Wang. Chronic Hepatitis B: A Critical Discussion. Future Virology 2017; 12(3): 111 doi: 10.2217/fvl-2016-0094
|
| 15 |
Min-Yu Lan, Hui-Chen Lin, Tsung-Hui Hu, Shu-Fang Chen, Chien-Hung Chen, Yung-Yee Chang, King-Wah Chiu, Tsu-Kung Lin, Shun-Sheng Chen. Telbivudine-Induced Myopathy: Clinical Features, Histopathological Characteristics, and Risk Factors. Journal of Clinical Neurology 2023; 19(1): 52 doi: 10.3988/jcn.2023.19.1.52
|
| 16 |
Jinxin Zheng, Minggui Deng, Xiaoliang Qiu, Zhong Chen, Duoyun Li, Xiangbin Deng, Qiwen Deng, Zhijian Yu. Rhabdomyolysis, lactic acidosis, and multiple organ failure during telbivudine treatment for hepatitis B: a case report and review of the literature. Journal of Medical Case Reports 2017; 11(1) doi: 10.1186/s13256-017-1498-6
|
| 17 |
Ramesh Kumar, Divendu Bhushan. Letter: lactic acidosis during anti‐viral therapy in patients with hepatitis B virus infection: A note of caution. GastroHep 2019; 1(5): 256 doi: 10.1002/ygh2.358
|
| 18 |
Jianping Zhao, Jingjing Wang, Songshan Chai, Yuxin Zhang, Wanguang Zhang. Elevated lactate impairs the efficacy of antiviral treatment on post-hepatectomy survival for advanced stage hepatitis B virus – related hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology 2019; 43(1): 67 doi: 10.1016/j.clinre.2018.08.008
|
| 19 |
Josef Finsterer, Sinda Zarrouk-Mahjoub. Treatment of muscle weakness in neuromuscular disorders. Expert Review of Neurotherapeutics 2016; 16(12): 1383 doi: 10.1080/14737175.2016.1206471
|